Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | ABL1 | P00519 | 10/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068201 | 0.87 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL6067936 | 0.83 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL6068377 | 0.78 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL6067763 | 0.78 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| SCHEMBL1842324 | 0.76 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL6068260 | 0.76 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA | |
| Hydrochloric Acid SCHEMBL1844043 | 0.75 | NPC1 (0.97) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL6068162 | 0.75 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2ABL1PIK3CD | |
| SCHEMBL6067996 | 0.75 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2ABL1 | |
| SCHEMBL6067954 | 0.75 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2ABL1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091227-B2 | Benzothiazole derivatives | ABBOTT GMBH & CO. KG (DE) | 2006-08-15 | — | — | US | disclosed |
| US-20030153568-A1 | Benzothiazole derivatives | BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY | 2003-08-14 | — | — | US | disclosed |
| EP-1254123-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Abbott GmbH & Co. KG (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001057008-A1 | 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153568-A1 | Benzothiazole derivatives | TK1, FLT1, CDK1 | NPC1 3594/4885RAB9A 3285/4885SMN1; SMN2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.